CY1115619T1 - Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων - Google Patents

Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων

Info

Publication number
CY1115619T1
CY1115619T1 CY20141100766T CY141100766T CY1115619T1 CY 1115619 T1 CY1115619 T1 CY 1115619T1 CY 20141100766 T CY20141100766 T CY 20141100766T CY 141100766 T CY141100766 T CY 141100766T CY 1115619 T1 CY1115619 T1 CY 1115619T1
Authority
CY
Cyprus
Prior art keywords
finalylkyl
exclusives
amin
calcium
short action
Prior art date
Application number
CY20141100766T
Other languages
English (en)
Inventor
Martin P Maguire
Elise Rioux
Harry J Leighton
Original Assignee
Milestone Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milestone Pharmaceuticals Inc. filed Critical Milestone Pharmaceuticals Inc.
Publication of CY1115619T1 publication Critical patent/CY1115619T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση μίας φαρμακευτικά αποτελεσματικής ποσότητας μίας ένωσης αποκλεισμού διαύλων ασβεστίου βραχείας δράσεως στην θεραπεία ισχαιμικών καρδιακών καταστάσεων, καρδιακών αρρυθμιών, υπερτασικής κρίσης σε ένα περιβάλλον δωματίου επειγόντων περιστατικών, υπέρτασης πριν, κατά τη διάρκεια, ή μετά την εγχείρηση, φαινόμενου μη επαναρροής μετά από υπεραιμάτωση, και μίας νόσου που συνδέεται με μειωμένη αιματική ροή στους σκελετικούς μύες. Η εφεύρεση σχετίζεται επίσης με φαρμακευτικές συνθέσεις για χρήση σε τέτοιες μεθόδους και με κιτ για τέτοιες μεθόδους.
CY20141100766T 2007-06-20 2014-09-18 Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων CY1115619T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93644007P 2007-06-20 2007-06-20
EP08768636.6A EP2170050B1 (en) 2007-06-20 2008-06-19 Short acting phenylalkylamine calcium channel blockers and uses thereof

Publications (1)

Publication Number Publication Date
CY1115619T1 true CY1115619T1 (el) 2017-01-04

Family

ID=40156562

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100766T CY1115619T1 (el) 2007-06-20 2014-09-18 Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων

Country Status (19)

Country Link
US (16) US20100190852A1 (el)
EP (1) EP2170050B1 (el)
JP (1) JP5421908B2 (el)
KR (1) KR101541557B1 (el)
CN (1) CN101754678B (el)
AU (1) AU2008266798B2 (el)
BR (1) BRPI0812919B8 (el)
CA (1) CA2693627C (el)
CY (1) CY1115619T1 (el)
DK (1) DK2170050T3 (el)
ES (1) ES2498047T3 (el)
HK (1) HK1140913A1 (el)
HR (1) HRP20140801T1 (el)
MX (1) MX347325B (el)
NZ (1) NZ582033A (el)
PL (1) PL2170050T3 (el)
PT (1) PT2170050E (el)
SI (1) SI2170050T1 (el)
WO (1) WO2008156820A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof
KR101052620B1 (ko) * 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
ES2543470T3 (es) * 2009-09-30 2015-08-19 Microdose Therapeutx, Inc. Métodos y composiciones para el tratamiento del fenómeno de Raynaud
WO2015073919A1 (en) * 2013-11-14 2015-05-21 University Medical Pharmaceuticals Corporation Microneedles for therapeutic agent delivery with improved mechanical properties
DK3283067T3 (da) * 2015-04-14 2020-03-30 Milestone Pharmaceuticals Inc Meget vandopløselige salte af korttidsvirkende calciumkanalblokkere på basis af phenylalkylamin og anvendelser heraf
US20230065401A1 (en) * 2021-07-15 2023-03-02 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3957845A (en) * 1962-04-27 1976-05-18 Knoll A.G. Chemische Fabriken Trifluoromethyl-substituted phenyl acetonitriles
DE1493904A1 (de) * 1965-07-31 1969-06-19 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE2059923C3 (de) * 1970-12-05 1979-01-25 Knoll Ag, 6700 Ludwigshafen l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
JPS5118940B2 (el) 1971-12-25 1976-06-14
DE2631222C3 (de) * 1976-07-12 1979-01-04 Knoll Ag, 6700 Ludwigshafen Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE3144150A1 (de) * 1981-04-10 1982-12-09 Basf Ag, 6700 Ludwigshafen (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel
DE3433383A1 (de) * 1984-09-12 1986-03-20 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phenyl-acetonitril-derivate
DE3603032A1 (de) * 1986-01-31 1987-08-06 Basf Ag Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel
US4833162A (en) * 1988-02-03 1989-05-23 American Cyanamid Company Substituted benzeneacetonitriles and their use as calcium channel blockers
PT96283A (pt) 1989-12-21 1991-09-30 Searle & Co Metodos de utilizacao de 2-isopropil-2-fenilaminovaleronitrilos como imunossupressores e vasodilatadores
US5486539A (en) * 1989-12-21 1996-01-23 G. D. Searle & Co. Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5162569A (en) * 1989-12-21 1992-11-10 G. D. Searle & Co. Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US5247119A (en) * 1990-12-12 1993-09-21 G. D. Searle & Co. Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5451604A (en) * 1993-07-26 1995-09-19 G. D. Searle & Co. Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives
US5910601A (en) * 1994-09-26 1999-06-08 Darwin Discovery Limited Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues
US5859279A (en) 1996-09-10 1999-01-12 Darwin Discovery Limited Compound and process
US6750238B1 (en) 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
US7511077B2 (en) * 2005-02-09 2009-03-31 Neuromed Pharmaceuticals Ltd. Diamine calcium channel blockers
GB2435824A (en) 2006-03-09 2007-09-12 Esteve Labor Dr Use of nitrile compounds in the treatment of food related and other disorders
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof

Also Published As

Publication number Publication date
US20180280339A1 (en) 2018-10-04
CA2693627A1 (en) 2008-12-24
KR20100043175A (ko) 2010-04-28
BRPI0812919B8 (pt) 2021-05-25
US20140296335A1 (en) 2014-10-02
EP2170050B1 (en) 2014-06-18
US20210315855A1 (en) 2021-10-14
PT2170050E (pt) 2014-09-04
US20100190852A1 (en) 2010-07-29
US20160074354A1 (en) 2016-03-17
MX347325B (es) 2017-04-12
US20160374982A1 (en) 2016-12-29
PL2170050T3 (pl) 2014-12-31
JP2010530429A (ja) 2010-09-09
US20210059972A1 (en) 2021-03-04
US20170312243A1 (en) 2017-11-02
JP5421908B2 (ja) 2014-02-19
AU2008266798A1 (en) 2008-12-24
CA2693627C (en) 2016-01-12
US20170312242A1 (en) 2017-11-02
US10010523B2 (en) 2018-07-03
HK1140913A1 (en) 2010-10-29
BRPI0812919B1 (pt) 2019-01-29
HRP20140801T1 (hr) 2014-11-21
DK2170050T3 (da) 2014-09-29
MX2009014052A (es) 2010-03-01
WO2008156820A1 (en) 2008-12-24
CN101754678B (zh) 2014-04-16
US20220142963A1 (en) 2022-05-12
US20200230097A1 (en) 2020-07-23
US10010524B2 (en) 2018-07-03
US9463179B2 (en) 2016-10-11
EP2170050A4 (en) 2010-11-24
US10010522B2 (en) 2018-07-03
US20240115543A1 (en) 2024-04-11
NZ582033A (en) 2012-07-27
EP2170050A1 (en) 2010-04-07
US20190142781A1 (en) 2019-05-16
CN101754678A (zh) 2010-06-23
US20170312241A1 (en) 2017-11-02
ES2498047T3 (es) 2014-09-24
BRPI0812919A2 (pt) 2014-10-07
US20230255923A1 (en) 2023-08-17
US20190380993A1 (en) 2019-12-19
SI2170050T1 (sl) 2014-12-31
KR101541557B1 (ko) 2015-08-03
US9227918B2 (en) 2016-01-05
US9737503B2 (en) 2017-08-22
AU2008266798B2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
CY1115619T1 (el) Αποκλειστες διαυλου ασβεστιου φαινυλαλκυλ αμινης βραχειας δρασεως και χρησεις αυτων
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
PA8724201A1 (es) Piridin[3,4b] pirazinonas
ECSP077180A (es) Compuestos, composiciones y métodos
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
ATE505220T1 (de) Graft-fixierung
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BR112012013329A2 (pt) composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
CY1112058T1 (el) Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων